PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Sinclair & Co.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Metrics Scientist Presents Case Study During AAPS Poster Session - Successfully increasing capsule potency using roller compaction
Metrics Scientist Presents Case Study During AAPS Poster Session


NewswireToday - /newswire/ - Greenville, NC, United States, 2010/11/18 - Successfully increasing capsule potency using roller compaction.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


While the client’s request of Metrics Inc. seemed simple enough – let’s double the potency of a particular capsule – fulfilling the request proved somewhat more complicated.

The successful meeting of the client’s need not only demonstrated Metrics Inc.’s expertise in pharmaceutical formulation, it also provided case study material for Joe Cobb Jr., CPIP, to present in a poster session Nov. 17 at the American Association of Pharmaceutical Scientists annual conference.

Cobb, senior formulations scientist at Metrics, discussed how his team increased the drug load and potency of a capsule formulation by converting it from a simple powder blend to roller compaction.

The case study began when a Metrics client requested that the active ingredient in its 60-milligram capsule be increased to 120-milligram strength.

The original powder blend formulation for the 60-milligram capsule contained 25 percent by weight of the active pharmaceutical ingredient (API) that had been micronized to d90<10 micron with inactive ingredients including pre-gelatinized starch, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate.

Together, the ingredients were hand-sifted and blended in a low-shear tumble blender before being encapsulated into standard size 2 hard gelatin capsules using an H&K 400 encapsulator and weight-sorted with a Sade P2/P4 automated sorter. Because of the final blend’s density, the original formulation was limited to doses of up to 60 milligrams API.

In order to achieve 120-milligram potency in a size 1 capsule, the Metrics team increased the drug load of the 60-milligram formulation from 25 percent to 38.7 percent by weight, and adjusted excipient levels and the blend’s density using roller compaction and milling. Extragranular blending and lubrication was performed in a low-shear tumble blender. Capsules were filled on an H&K 400 encapsulator and weight-sorted with a Sade P2/P4 automated sorter.

Metrics scientists conducted blend testing comparisons of the two formulations, including flowability through minimum orifice and bulk density. Their drug product comparisons included potency determination, dissolution, uniformity of dosage units (USP <905>) by weight variation and yield following weight sorting.

What they found was that flowability was identical for both blends. The bulk density of the roller compacted material was nearly 50 percent higher than for the original blend. Capsule assays and dissolution for both manufacturing methods conformed to specifications, while uniformity of dosage units acceptance value improved from 9.3 percent to 6.7 percent after roller compacting. The product yield after weight sorting increased from 65 percent to 84 percent after converting the powder blend formulation to roller compaction.

Metrics concluded that they could successfully increase the potency formulation of a capsule using roller compaction.
“These are common technologies within our industry, so the information presented at AAPS in this case study is not completely novel,” Cobb said. “But our case study does demonstrate the formulation development experience and capabilities that Metrics offers clients, and confirms with actual data some theories that are general to our industry. It also highlights Metrics’ culture of positively collaborating with our clients for the successful completion of their project.”

Metrics, Inc. ( is one of the most respected contract pharmaceutical development and manufacturing companies in the United States today. Started as an analytical laboratory in 1994, Metrics has evolved into a full-service provider of quality pharmaceutical formulation development; first-time-in-man (FTIM) formulations; clinical material manufacturing (CTM) for Phase I, II and III trials; commercial manufacturing; and analytical method development and validation services.

Metrics has particular expertise in FTIM and Phase I, II, and III CTM manufacturing, having conducted more than 120 FTIM projects for different chemical entities in the last five years alone – while developing more than 700 batches of CTM in the same period.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Sinclair & Co.


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

Metrics Scientist Presents Case Study During AAPS Poster Session

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Publisher Contact: Karen Stinneford - 
919-833-9102 kstinneford[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Sinclair & Co. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Sinclair & Co. / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy
Greenphire Continues Commitment to Clinical Research Site Sustainability and Innovation at Global Site Solutions Summit
Frost & Sullivan Highlights argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPL
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis
MDxHealth Announces Agreement with SouthGenetics for Distribution of SelectMDx in Central/South America
BD and Apax Partners Announce Closing of Joint Venture to Launch Global Respiratory Business
Exosome Diagnostics Enters Agreement with Amgen
Sartorius Stedim Biotech Launches Two Single-use Sartocon® Loop Assemblies with Integrated Polyethersulfone (PESU) Membrane
BD Expands Efforts to Combat Antimicrobial Resistance with New Automated ID/AST System

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  La Bella Bakery Artisan Bakery Arizona


  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (